| Bioactivity | Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research[1]. |
| Name | Ibalizumab |
| CAS | 680188-33-4 |
| Appearance | Lyophilized Powder |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785. |